HOME ·

09637.HK

ALEBUND-B (09637.HK): FDA Clears IND for First-in-class IgA Protease AP308 in IgA Nephropathy; First-in-human Trial to Commence
Tags：
ALEBUND-B09637.HKClinical Trial
2026-09-08
ALEBUND-B(09637.HK) closed 18.75% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector posted broad gains
Tags：
ALEBUND-B09637.HK
2026-07-03
ALEBUND-B(09637.HK) closed 44.47% lower, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
Tags：
ALEBUND-B09637.HK
2026-07-02
Alebund-B (09637.HK) Surges 103.54% on Listing Day, Closing at HK$46
Tags：
ALEBUND-B09637.HKListingDebut
2026-06-29
ALEBUND-B(09637.HK): Grey Market Surges 82.74% to HK$41.30
Tags：
ALEBUND-B09637.HKgrey market tradingIPO
2026-06-26
ALEBUND-B (09637.HK): IPO Subscription Period Closes, Margin Subscription Totals HK$40.611 Billion, Listing Scheduled for 29 June
Tags：
ALEBUND-B09637.HKIPO subscription period closesmargin subscription funds
2026-06-24
Alebund Pharmaceuticals (09637.HK) Launches IPO: Offer Price at HK$22.60 per Share, Listing Expected June 29
Tags：
Alebund Pharmaceuticals09637.HKIPO
2026-06-18